Home >> Pharmaceuticals >> Food & Beverage >>

Global mRNA Vaccines & Therapeutics Detailed Analysis Report 2017-2022

Published: Aug-2017 | Format: PDF | Detailed Analysis Research | Number of pages: 118 | Code: MRS - 159501

This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in mRNA Vaccines & Therapeutics industry.

This report splits mRNA Vaccines & Therapeutics market By Cancer Vaccines, By Infectious Disease Vaccines, By In vivo Therapeutics, By Gene Editing, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022.

This report focuses Global market, it covers details as following:

Major Companies

  • Argos Therapeutics (U.S.)
  • AstraZeneca (UK)
  • Bayer AG (Germany)
  • BioNTech (Germany)
  • Boehringer Ingelheim (Germany)
  • CRISPR Therapeutics (Switzerland)
  • CureVac (Germany)
  • ETheRNA immunotherapies (Belgium)
  • Ethris (Germany)
  • GlaxoSmithKline Vaccines (UK)
  • In-Cell-Art (France)
  • Intellia Therapeutics (U.S.)
  • Janssen (Belhium)
  • Kernal Biologics (U.S.)
  • MaxCyte (U.S.)
  • Moderna Therapeutics (U.S.)
  • Novartis (U.S.)
  • PhaseRx (U.S.)
  • Precision NanoSystems (Canada)
  • RaNa Therapeutics (U.S.)

Main Regions

  • North America
  • United States
  • Canada
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Russia
  • Netherland
  • Others
  • Asia & Pacific
  • China
  • Japan
  • India
  • Korea
  • Australia
  • Southeast Asia
  • Indonesia
  • Thailand
  • Philippines
  • Vietnam
  • Singapore
  • Malaysia
  • Others
  • Africa & Middle East
  • South Africa
  • Egypt
  • Turkey
  • Saudi Arabia
  • Iran
  • Others

Main Product Type

  • mRNA Vaccines & Therapeutics Market, by Cancer Vaccines
  • Standardized preselected
  • Individualized shared antigens
  • Individualized neoantigens
  • mRNA Vaccines & Therapeutics Market, by Infectious Disease Vaccines
  • Prophylactic vaccines
  • Therapeutic vaccines
  • Synthetic self-amplifying mRNA vaccines for pandemic outbreaks
  • mRNA Vaccines & Therapeutics Market, by In vivo Therapeutics
  • Therapeutic proteins
  • Therapeutic antibodies
  • mRNA Vaccines & Therapeutics Market, by Gene Editing
  • Ex vivo gene editing of gene defects
  • In vivo gene editing of gene defects
  • Ex vivo gene editing of autologous and allogeneic T-cells

Main Applications

  • Hospital
  • Clinic
  • Others

Table of Contents

Global mRNA Vaccines & Therapeutics Detailed Analysis Report 2017-2022
Chapter One mRNA Vaccines & Therapeutics Market Overview
    1.1 Global mRNA Vaccines & Therapeutics Market Sales Volume Revenue and Price 2012-2022
    1.2 mRNA Vaccines & Therapeutics, By Cancer Vaccines 2012-2022
        1.2.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Cancer Vaccines 2012-2022
        1.2.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Cancer Vaccines 2012-2022
        1.2.3 Global mRNA Vaccines & Therapeutics Price by Cancer Vaccines 2012-2022
        1.2.4 Standardized preselected
        1.2.5 Individualized shared antigens
        1.2.6 Individualized neoantigens
    1.3 mRNA Vaccines & Therapeutics, by Infectious Disease Vaccines 2012-2022
        1.3.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Infectious Disease Vaccines 2012-2022
        1.3.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Infectious Disease Vaccines 2012-2022
        1.3.3 Global mRNA Vaccines & Therapeutics Price by Infectious Disease Vaccines 2012-2022
        1.3.4 Prophylactic vaccines
        1.3.5 Therapeutic vaccines
        1.3.6 Synthetic self-amplifying mRNA vaccines for pandemic outbreaks
    1.4 mRNA Vaccines & Therapeutics, by In vivo Therapeutics 2012-2022
        1.4.1 Global mRNA Vaccines & Therapeutics Sales Market Share by In vivo Therapeutics 2012-2022
        1.4.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by In vivo Therapeutics 2012-2022
        1.4.3 Global mRNA Vaccines & Therapeutics Price by In vivo Therapeutics 2012-2022
        1.4.4 Therapeutic proteins
        1.4.5 Therapeutic antibodies
    1.5 mRNA Vaccines & Therapeutics, by Gene Editing 2012-2022
        1.5.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Gene Editing 2012-2022
        1.5.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Gene Editing 2012-2022
        1.5.3 Global mRNA Vaccines & Therapeutics Price by Gene Editing 2012-2022
        1.5.4 Ex vivo gene editing of gene defects
        1.5.5 In vivo gene editing of gene defects
        1.5.6 Ex vivo gene editing of autologous and allogeneic T-cells

Chapter Two mRNA Vaccines & Therapeutics by Regions 2012-2017
    2.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Regions 2012-2017
    2.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Regions 2012-2017
    2.3 Global mRNA Vaccines & Therapeutics Price by Regions 2012-2017
    2.4 North America
        2.4.1 United States
        2.4.2 Canada
    2.5 Latin America
        2.5.1 Mexico
        2.5.2 Brazil
        2.5.3 Argentina
        2.5.4 Others in Latin America
    2.6 Europe
        2.6.1 Germany
        2.6.2 United Kingdom
        2.6.3 France
        2.6.4 Italy
        2.6.5 Spain
        2.6.6 Russia
        2.6.7 Netherland
        2.6.8 Others in Europe
    2.7 Asia & Pacific
        2.7.1 China
        2.7.2 Japan
        2.7.3 India
        2.7.4 Korea
        2.7.5 Australia
        2.7.6 Southeast Asia
            2.7.6.1 Indonesia
            2.7.6.2 Thailand
            2.7.6.3 Philippines
            2.7.6.4 Vietnam
            2.7.6.5 Singapore
            2.7.6.6 Malaysia
            2.7.6.7 Others in Southeast Asia
    2.8 Africa & Middle East
        2.8.1 South Africa
        2.8.2 Egypt
        2.8.3 Turkey
        2.8.4 Saudi Arabia
        2.8.5 Iran
        2.8.6 Others in Africa & Middle East

Chapter Three mRNA Vaccines & Therapeutics by Players 2012-2017
    3.1 Global mRNA Vaccines & Therapeutics Sales Volume Market Share by Players 2012-2017
    3.2 Global mRNA Vaccines & Therapeutics Revenue Share by Players 2012-2017
    3.3 Global Top Players mRNA Vaccines & Therapeutics Key Product Model and Market Performance
    3.4 Global Top Players mRNA Vaccines & Therapeutics Key Target Consumers and Market Performance

Chapter Four mRNA Vaccines & Therapeutics by Consumer 2012-2017
    4.1 Global mRNA Vaccines & Therapeutics Sales Market Share by Consumer 2012-2017
    4.2 Hospital
    4.3 Clinic
    4.4 Others
    4.5 Consuming Habit and Preference

Chapter Five Global Top Players Profile
    5.1 Argos Therapeutics (U.S.)
        5.1.1 Argos Therapeutics (U.S.) Company Details and Competitors
        5.1.2 Argos Therapeutics (U.S.) Key mRNA Vaccines & Therapeutics Models and Performance
        5.1.3 Argos Therapeutics (U.S.) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.1.4 Argos Therapeutics (U.S.) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.2 AstraZeneca (UK)
        5.2.1 AstraZeneca (UK) Company Details and Competitors
        5.2.2 AstraZeneca (UK) Key mRNA Vaccines & Therapeutics Models and Performance
        5.2.3 AstraZeneca (UK) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.2.4 AstraZeneca (UK) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.3 Bayer AG (Germany)
        5.3.1 Bayer AG (Germany) Company Details and Competitors
        5.3.2 Bayer AG (Germany) Key mRNA Vaccines & Therapeutics Models and Performance
        5.3.3 Bayer AG (Germany) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.3.4 Bayer AG (Germany) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.4 BioNTech (Germany)
        5.4.1 BioNTech (Germany) Company Details and Competitors
        5.4.2 BioNTech (Germany) Key mRNA Vaccines & Therapeutics Models and Performance
        5.4.3 BioNTech (Germany) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.4.4 BioNTech (Germany) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.5 Boehringer Ingelheim (Germany)
        5.5.1 Boehringer Ingelheim (Germany) Company Details and Competitors
        5.5.2 Boehringer Ingelheim (Germany) Key mRNA Vaccines & Therapeutics Models and Performance
        5.5.3 Boehringer Ingelheim (Germany) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.5.4 Boehringer Ingelheim (Germany) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.6 CRISPR Therapeutics (Switzerland)
        5.6.1 CRISPR Therapeutics (Switzerland) Company Details and Competitors
        5.6.2 CRISPR Therapeutics (Switzerland) Key mRNA Vaccines & Therapeutics Models and Performance
        5.6.3 CRISPR Therapeutics (Switzerland) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.6.4 CRISPR Therapeutics (Switzerland) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.7 CureVac (Germany)
        5.7.1 CureVac (Germany) Company Details and Competitors
        5.7.2 CureVac (Germany) Key mRNA Vaccines & Therapeutics Models and Performance
        5.7.3 CureVac (Germany) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.7.4 CureVac (Germany) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.8 ETheRNA immunotherapies (Belgium)
        5.8.1 ETheRNA immunotherapies (Belgium) Company Details and Competitors
        5.8.2 ETheRNA immunotherapies (Belgium) Key mRNA Vaccines & Therapeutics Models and Performance
        5.8.3 ETheRNA immunotherapies (Belgium) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.8.4 ETheRNA immunotherapies (Belgium) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.9 Ethris (Germany)
        5.9.1 Ethris (Germany) Company Details and Competitors
        5.9.2 Ethris (Germany) Key mRNA Vaccines & Therapeutics Models and Performance
        5.9.3 Ethris (Germany) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.9.4 Ethris (Germany) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.10 GlaxoSmithKline Vaccines (UK)
        5.10.1 GlaxoSmithKline Vaccines (UK) Company Details and Competitors
        5.10.2 GlaxoSmithKline Vaccines (UK) Key mRNA Vaccines & Therapeutics Models and Performance
        5.10.3 GlaxoSmithKline Vaccines (UK) mRNA Vaccines & Therapeutics Business SWOT Analysis and Forecast
        5.10.4 GlaxoSmithKline Vaccines (UK) mRNA Vaccines & Therapeutics Sales Volume Revenue Price Cost and Gross Margin
    5.11 In-Cell-Art (France)
    5.12 Intellia Therapeutics (U.S.)
    5.13 Janssen (Belhium)
    5.14 Kernal Biologics (U.S.)
    5.15 MaxCyte (U.S.)
    5.16 Moderna Therapeutics (U.S.)
    5.17 Novartis (U.S.)
    5.18 PhaseRx (U.S.)
    5.19 Precision NanoSystems (Canada)
    5.20 RaNa Therapeutics (U.S.)

Chapter Six Industry Chain and Supply Chain
    6.1 mRNA Vaccines & Therapeutics Industry Chain Structure
        6.1.1 R&D
        6.1.2 Raw Materials (Components)
        6.1.3 Manufacturing Plants
        6.1.4 Regional Trading (Import Export and Local Sales)
        6.1.5 Online Sales Channel
        6.1.6 Offline Channel
        6.1.7 End Users
    6.2 mRNA Vaccines & Therapeutics Manufacturing
        6.2.1 Key Components
        6.2.2 Assembly Manufacturing
    6.3 Consumer Preference
    6.4 Behavioral Habits
    6.5 Marketing Environment

Chapter Seven Global mRNA Vaccines & Therapeutics Market Size (Sales and Revenue) Forecast (2017-2022)
    7.1 Global mRNA Vaccines & Therapeutics Sales (Million Units), Revenue (Million USD) Forecast (2017-2022)
    7.2 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by Regions (2017-2022)
    7.3 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by Application (2017-2022)
    7.4 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by Cancer Vaccines (2017-2022)
    7.5 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by Infectious Disease Vaccines (2017-2022)
    7.6 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by In vivo Therapeutics (2017-2022)
    7.7 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by Gene Editing (2017-2022)
    7.8 Global mRNA Vaccines & Therapeutics Sales (Million Units) Forecast by  (2017-2022)

Chapter Eight Development Trend and Research Conclusion
    8.1 Development Trend
    8.2 Research Conclusion

Chapter Nine Methodology and Data Source
    9.1 Methodology/Research Approach
        9.1.1 Research Programs/Design
        9.1.2 Market Size Estimation
        9.1.3 Market Breakdown and Data Triangulation
    9.2 Data Source
        9.2.1 Secondary Sources
        9.2.2 Primary Sources
    9.3 Disclaimer



                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)3250 View Pricing